FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2126176994> ?p ?o ?g. }

• W2126176994 abstract "To evaluate activity and tolerability of two anthracycline-containing regimens as first-line treatment for anthracycline-naïve relapsed breast cancer patients.Patients with relapsed breast cancer not previously treated with adjuvant anthracyclines were randomly assigned to epirubicin/vinorelbine (arm A: EPI/VNB, EPI 90 mg/m2 on day 1, VNB 25 mg/m2 on days 1,5 plus G-CSF subcutaneously on days 7-12, with cycles repeated every 21 days), or to pegylated liposomal doxorubicin/VNB (arm B: PLD/VNB, PLD 40 mg/m2 on day 1, VNB 30 mg/m2 on days 1, 15, with cycles repeated every 4 weeks). Primary objective was to evaluate the efficacy of the two regimens in terms of response rate, secondarily toxicity, progression free survival and overall survival.One hundred and four patients have been enrolled (arm A 54, arm B 50): characteristics were well balanced between the 2 arms. Responses were as follows: arm A, 3 (5.6%) CR, 20 (37%) PR, (ORR 42.6%, 95%CI 29.3%-55.9%); arm B, 8 (16%) CR, 18 (36%) PR, (ORR 52%, 95%CI 38.2%-65.8%). Median progression free survival was 10.7 months in arm A (95% CI, 8.7-12.6), and 8.8 months in arm B (95% CI, 7.1-10.5). Median overall survival was 34.6 months in arm A (95%CI, 19.5-49.8) and 24.8 months in arm B (95%CI, 15.7-33.9). As toxicity concerns, both treatment regimens were well tolerated; myelosuppression was the dose-limiting toxicity, with G3-4 neutropenia occurring in 18.5% and 22% of the patients of arm A and B, respectively. No relevant differences in main toxic effects have been observed between the two arms, except for alopecia, more common in arm A, and cutaneous toxicity, observed only in arm B. No clinical congestive heart failures have been observed, one case of tachyarrhythmia was reported after the last EPI/VNB cycle, and two reversible ≥ 20% LVEF decreases have been observed in arm A.Both anthracycline- containing regimens evaluated in the present study seem to be active and with a satisfactory tolerability in anthracycline-naïve relapsed breast cancer patients." @default.
• W2126176994 created "2016-06-24" @default.
• W2126176994 creator A5004830992 @default.
• W2126176994 creator A5010531543 @default.
• W2126176994 creator A5019614566 @default.
• W2126176994 creator A5021898630 @default.
• W2126176994 creator A5025243663 @default.
• W2126176994 creator A5028896072 @default.
• W2126176994 creator A5032104630 @default.
• W2126176994 creator A5037761585 @default.
• W2126176994 creator A5062643447 @default.
• W2126176994 creator A5062971539 @default.
• W2126176994 creator A5065513710 @default.
• W2126176994 creator A5071630640 @default.
• W2126176994 creator A5076498258 @default.
• W2126176994 creator A5086743021 @default.
• W2126176994 date "2011-04-12" @default.
• W2126176994 modified "2023-10-14" @default.
• W2126176994 title "A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study" @default.
• W2126176994 cites W12356482 @default.
• W2126176994 cites W1783154753 @default.
• W2126176994 cites W1811085086 @default.
• W2126176994 cites W1843618725 @default.
• W2126176994 cites W1911376378 @default.
• W2126176994 cites W1957304651 @default.
• W2126176994 cites W1978765248 @default.
• W2126176994 cites W1981180604 @default.
• W2126176994 cites W1984851804 @default.
• W2126176994 cites W1992316210 @default.
• W2126176994 cites W2006499683 @default.
• W2126176994 cites W2011223682 @default.
• W2126176994 cites W2024003853 @default.
• W2126176994 cites W2027355084 @default.
• W2126176994 cites W2047203002 @default.
• W2126176994 cites W2048772541 @default.
• W2126176994 cites W2051297618 @default.
• W2126176994 cites W2070825008 @default.
• W2126176994 cites W2083168801 @default.
• W2126176994 cites W2096593771 @default.
• W2126176994 cites W2113016864 @default.
• W2126176994 cites W2117194901 @default.
• W2126176994 cites W2120113475 @default.
• W2126176994 cites W2129765581 @default.
• W2126176994 cites W2139248078 @default.
• W2126176994 cites W2145946420 @default.
• W2126176994 cites W2148845753 @default.
• W2126176994 cites W2157470118 @default.
• W2126176994 cites W2164203329 @default.
• W2126176994 cites W2168047835 @default.
• W2126176994 cites W2183288147 @default.
• W2126176994 cites W2270235662 @default.
• W2126176994 cites W2271753451 @default.
• W2126176994 cites W2340435826 @default.
• W2126176994 cites W4244497714 @default.
• W2126176994 doi "https://doi.org/10.1186/1756-9966-30-39" @default.
• W2126176994 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3082232" @default.
• W2126176994 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21481280" @default.
• W2126176994 hasPublicationYear "2011" @default.
• W2126176994 type Work @default.
• W2126176994 sameAs 2126176994 @default.
• W2126176994 citedByCount "19" @default.
• W2126176994 countsByYear W21261769942013 @default.
• W2126176994 countsByYear W21261769942014 @default.
• W2126176994 countsByYear W21261769942015 @default.
• W2126176994 countsByYear W21261769942016 @default.
• W2126176994 countsByYear W21261769942018 @default.
• W2126176994 countsByYear W21261769942019 @default.
• W2126176994 countsByYear W21261769942021 @default.
• W2126176994 crossrefType "journal-article" @default.
• W2126176994 hasAuthorship W2126176994A5004830992 @default.
• W2126176994 hasAuthorship W2126176994A5010531543 @default.
• W2126176994 hasAuthorship W2126176994A5019614566 @default.
• W2126176994 hasAuthorship W2126176994A5021898630 @default.
• W2126176994 hasAuthorship W2126176994A5025243663 @default.
• W2126176994 hasAuthorship W2126176994A5028896072 @default.
• W2126176994 hasAuthorship W2126176994A5032104630 @default.
• W2126176994 hasAuthorship W2126176994A5037761585 @default.
• W2126176994 hasAuthorship W2126176994A5062643447 @default.
• W2126176994 hasAuthorship W2126176994A5062971539 @default.
• W2126176994 hasAuthorship W2126176994A5065513710 @default.
• W2126176994 hasAuthorship W2126176994A5071630640 @default.
• W2126176994 hasAuthorship W2126176994A5076498258 @default.
• W2126176994 hasAuthorship W2126176994A5086743021 @default.
• W2126176994 hasBestOaLocation W21261769941 @default.
• W2126176994 hasConcept C121608353 @default.
• W2126176994 hasConcept C126322002 @default.
• W2126176994 hasConcept C141071460 @default.
• W2126176994 hasConcept C143998085 @default.
• W2126176994 hasConcept C197934379 @default.
• W2126176994 hasConcept C2775930923 @default.
• W2126176994 hasConcept C2776694085 @default.
• W2126176994 hasConcept C2776802502 @default.
• W2126176994 hasConcept C2778239845 @default.
• W2126176994 hasConcept C2778375690 @default.
• W2126176994 hasConcept C2780350996 @default.
• W2126176994 hasConcept C2780835546 @default.
• W2126176994 hasConcept C530470458 @default.
• W2126176994 hasConcept C71924100 @default.
• W2126176994 hasConcept C90924648 @default.
• W2126176994 hasConceptScore W2126176994C121608353 @default.

• next